Voyager names Swartz president. USD 107.2 million values Voyager Therapeutics stock

Published on 10/25/2026 at 13:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Robin Swartz became president on October 20, 2026. Voyager Therapeutics stock had USD 107.2 million market value after October 23, 2026 trading.

Leadership transition and operating figures

Robin Swartz became president on October 20, 2026, ahead of a planned first-quarter 2027 CEO transition.
Voyager ended the second quarter of 2026 with USD 149.0 million in cash and a runway into 2028.
Voyager Therapeutics stock had a USD 107.2 million market value on October 23, 2026.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics (ISIN US92915B1061) appointed Robin Swartz president on October 20, 2026, as the biotechnology company prepares a planned CEO transition in the first quarter of 2027. The announcement gives investors a leadership milestone to track alongside clinical data from VY1706, Voyager's investigational tau-silencing gene therapy for early Alzheimer's disease.

Swartz takes the next leadership role

According to GlobeNewswire on October 21, 2026, the board appointed Swartz president effective October 20 and expects her to succeed Alfred W. Sandrock as CEO after initial acute safety data from VY1706. Sandrock is expected to remain CEO through that milestone and then continue as a board member.

The succession plan links management continuity to a clinical timetable. The release places the initial VY1706 safety data in the first quarter of 2027, pending enrollment, making the data release the next major operational marker for the company.

What does the cash position mean?

Voyager's second-quarter 2026 results included USD 149.0 million of cash and a stated runway into 2028, according to the company release carried by GlobeNewswire. That liquidity frame matters because the company remains focused on advancing clinical programs rather than commercial product sales.

Three milestones shape the timeline

On August 6, 2026, Voyager reported second-quarter results and said its cash position was USD 149.0 million. On September 28, 2026, Voyager completed a USD 402.5 million convertible senior notes offering, as listed by 6ix. On October 21, 2026, the company disclosed the Swartz appointment and the first-quarter 2027 succession plan.

Dates investors can measure

The next stated milestone is the first quarter of 2027 for initial VY1706 acute safety data. The clinical entry and related VY1706 data were also described for the fourth quarter of 2026 in the company's second-quarter update, creating two dated development checkpoints for the pipeline.

Market value stays tightly linked to execution

Voyager's home listing is Nasdaq, where the stock closed at USD 1.74 on October 23, 2026. Its market capitalization was USD 107.2 million at that close, while the last available Frankfurt euro quote stood at EUR 1.58 on October 23, 2026. The valuation leaves clinical execution, enrollment and cash use as the central factors in the investment case.

The last available euro quote stood at EUR 1.58 on Frankfurt Stock Exchange on October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Voyager Therapeutics stock.